Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 21, 2014
Pharmacy Choice - News - Generic Drugs - December 21, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 38     Next >>     Go To Page:

12/20/14 - Actavis Considers Offer For Almirall : Report
MADRID- Generic drug maker Actavis plc is considering Spanish drugmaker Almirall SA as one of several possible takeover targets, Bloomberg reported citing people familiar with the matter said. The report said that Actavis has identified Almirall, which could be valued at about 3 billion euros or $3.7 billion in a deal, as one of its preferred targe
12/19/14 - Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Actavis plc, a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston, MA.. The presentation will take place on Tuesday, January 6, 2015 at 12:00 PM Eastern
12/19/14 - Akorn to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Akorn, Inc., a specialty generic pharmaceutical company, announced today that Raj Rai, Chief Executive Officer, will provide an overview and update of the Company's business at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 4:00 pm PST at the Westin St. Francis Hotel, San Francisco, California. Akorn, Inc. is a
12/19/14 - Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd.
Breckenridge Pharmaceutical, Inc. announced today that it has entered into a multi-product agreement with MSN Laboratories Pvt. Ltd. under which Breckenridge and MSN expect to commercialize several new ANDAs. Under the terms of the agreement, MSN will develop, manufacture, and supply the products exclusively to Breckenridge for the U.S. market, a
12/19/14 - Teva Announces FDA Approval of QNASL (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis
Teva Pharmaceutical Industries Ltd., announced today that the U.S. Food and Drug Administration approved QNASL 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis in children 4-11 years of age. Todd Mahr, MD, Director of Pediatric Allergy and Immunology at Gundersen Lutheran Medical Center in La Crosse, Wisconsin. QNA
12/18/14 - Amneal Pharmaceuticals, LLC Selects Revitas Revenue Management Suite
Revitas, Inc., the leading provider of integrated solutions for contract, revenue, and compliance management, today announced that Amneal Pharmaceuticals, one of the largest generic drug suppliers in the U.S., has selected the Revitas suite of revenue management solutions to support global growth and meet expanded business requirements.
12/18/14 - Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim
Release date- 17122014- Toronto, ON- Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of Amgen's Neulasta. The product has been jointly developed with Intas Pharmaceuticals Ltd. The applic
12/18/14 - Lannett Receives FDA Approval for Dorzolamide HCL with Timolol
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/ 0.5%, the therapeutic equivalent to the reference listed drug, Cosopt Ophthalmic Solution, 2%/ 0.5%, of Oak Pharmaceutica
12/18/14 - Providing Regulatory Submissions in Electronic FormatStandardized Study Data; Guidance for Industry; Availability
The guidance describes how FDA plans to implement the requirements for the electronic submission of standardized study data contained in certain submissions under new drug applications, abbreviated new drug applications, biologics license applications, and investigational new drug applications. ADDRESSES: Submit written requests for single copies..
12/18/14 - Putney Launches Carprofen Chewable Tablets
Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, announces today that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis' popular Rimadyl Chewable Tablets. With this product approval, the Company's fourth in less than three
12/18/14 - TPI New Qionglai Facility (QLF) Updates
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today updated that the pictures of TPI's Qionglai Facility are available on the front page of www.tianyinpharma.com. TPI currently manufactures..
12/17/14 - Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim
Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta . TORONTO, Dec. 17, 2014/ CNW/- Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of A
12/17/14 - Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
Report Details Biosimilar drugs discover trends and segments with highest potential revenues Do you want to find sales potentials of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2014, helping you stay ahead. For those therapies you find financial data, R&D trends, opportunities and sell
12/17/14 - BRIEF: US court delays Teva launch of generic Celebrex [Globes, Tel Aviv, Israel]
Consequently, Teva will be compelled to wait until June 2015 before being allowed to launch the generic version of the arthritis, inflammation and chronic pain treatment, which earns Pfizer $3 billion annually. Last week Teva had announced that it would be immediately launching an exclusive version of generic Celebrex after becoming the first to re
12/17/14 - Fitch Affirms Teva's Ratings at 'BBB+'; Outlook Stable
Teva is the world's largest generic drug manufacturer and a top-20 global pharmaceutical company. The risk remains that Teva's top-selling drug, Copaxone, could face generic competition in the U.S. at any time and by May 2015 in most of Europe. However, this risk has been mitigated by Teva's successful conversion of nearly two-thirds of U.S. pa
12/17/14 - Latest Report: Generic and Innovative Drugs Market in CIS Countries 2014 Russia, Ukraine and Kazakhstan Development Forecasts for 2014-2019
The Report Generic and Innovative Drugs Market in CIS Countries 2014 Russia, Ukraine and Kazakhstan Development Forecasts for 2014-2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.- MarketResearchReports.bizAlbany, NY 12/17/2014 Compare and analyse generic and innovati
12/17/14 - Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33 rd Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco. The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 13, 2015.
12/17/14 - New Monoclonal Antibodies Findings Reported from Covance Laboratories Inc. [Comparative Nonclinical Assessments of the Proposed Biosimilar...
New Monoclonal Antibodies Findings Reported from Covance Laboratories Inc.. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States and European Union. " Our news editors obtained a quote from the research from Covance Laboratories Inc., "Nonclinical studies were designed to evaluate the simila
12/17/14 - New Pharmacoeconomics Study Results Reported from Erasmus University (Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case...
New Pharmacoeconomics Study Results Reported from Erasmus University. Our news journalists obtained a quote from the research from Erasmus University, "At this moment, the uptake of biosimilars in Belgium is limited, with market shares close to 0%. This study aimed to identify the barriers that impede the uptake of biosimilars in Belgium.
12/17/14 - Oncology Generics: Prepping Collaborations
With major cancer drugs slated for patent expirations in the next few years and big pharmas such as Eli Lilly foraying into the generics industry, generics are going to be the next big thing in the field of oncology. Recently, ScinoPharm Taiwan and Coland have formed a strategic partnership in order to develop a series of generic oncological drugs
12/17/14 - PATENTS EXPIRE IN 2016 [Bristol Evening Post (England)]
AstraZeneca's Avlon plant is used to make the active pharmaceutical ingredients for two of the firm's brands. Meanwhile generic versions of the other drug produced in Avonmouth are already available in the UK and US. The drug, Seroquel, is licensed in the UK for the treatment of bipolar disorder and schizophrenia.
12/17/14 - Stakeholders Urge FDA to Pass Final Guidance on Biosimilars at Recent Conference, AIS Newsletter Reports
The December issue of Atlantic Information Services, Inc.' s Specialty Pharmacy News offers coverage of a recent conference on biosimilars, drugs that are highly similar to and less expensive than brand-name biologic drugs and use an abbreviated pathway for the Food and Drug Administration's approval. At Rx Innovation: A Discussion on Biosimilars,
12/16/14 - Arbor Pharmaceuticals Updates on Wilshire Lastacaft Patent Challenge [Professional Services Close - Up]
Wilshire Pharmaceuticals confirmed that it has been sued by Allergan and Vistakon Pharmaceuticals in connection with Wilshire's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Alcaftadine 0.25 percent. Wilshire Pharmaceuticals is a generic pharmaceutical company. It is a subsidiary of Arbor...
12/16/14 - Dr. Reddy's Announces the Launch of Valganciclovir Tablets, USP
Reddy s Laboratories announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE tablets in the US market on December 15, 2014, approved by the United States Food& Drug Administration. The VALCYTE tablets brand had U.S. sales of approximately $440 Million MAT for the most rece
12/16/14 - PCI Synthesis Sponsors New England CRO/CMO Council
PCI Synthesis, Inc., a manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other specialty chemical products, announced that it is a sponsor and steering committee member of the New England CRO/CMO Council, along with Averica Discovery Services, Organix TGA Sciences, Inc. and CE3. The non-profit New England CRO/CMO
Articles(s): 1 - 25 of 38     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
Medication Errors: A Patient Safety and Quality Improvement Program
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415